Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8C0A

Crystal structure of JAK2 JH2-R683S

8C0A の概要
エントリーDOI10.2210/pdb8c0a/pdb
分子名称Tyrosine-protein kinase JAK2, GLYCEROL, 3,5-diphenyl-2-(trifluoromethyl)-1~{H}-pyrazolo[1,5-a]pyrimidin-7-one, ... (4 entities in total)
機能のキーワードjanus kinase, pseudokinase, jak2, jh2, transferase
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数2
化学式量合計66996.51
構造登録者
Haikarainen, T.,Silvennoinen, O. (登録日: 2022-12-16, 公開日: 2023-12-27, 最終更新日: 2024-10-23)
主引用文献Abraham, B.G.,Haikarainen, T.,Vuorio, J.,Girych, M.,Virtanen, A.T.,Kurttila, A.,Karathanasis, C.,Heilemann, M.,Sharma, V.,Vattulainen, I.,Silvennoinen, O.
Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.
Sci Adv, 10:eadl2097-eadl2097, 2024
Cited by
PubMed Abstract: Janus kinase 2 (JAK2) mediates type I/II cytokine receptor signaling, but JAK2 is also activated by somatic mutations that cause hematological malignancies by mechanisms that are still incompletely understood. Quantitative superresolution microscopy (qSMLM) showed that erythropoietin receptor (EpoR) exists as monomers and dimerizes upon Epo stimulation or through the predominant JAK2 pseudokinase domain mutations (V617F, K539L, and R683S). Crystallographic analysis complemented by kinase activity analysis and atomic-level simulations revealed distinct pseudokinase dimer interfaces and activation mechanisms for the mutants: JAK V617F activity is driven by dimerization, K539L involves both increased receptor dimerization and kinase activity, and R683S prevents autoinhibition and increases catalytic activity and drives JAK2 equilibrium toward activation state through a wild-type dimer interface. Artificial intelligence-guided modeling and simulations revealed that the pseudokinase mutations cause differences in the pathogenic full-length JAK2 dimers, particularly in the FERM-SH2 domains. A detailed molecular understanding of mutation-driven JAK2 hyperactivation may enable novel therapeutic approaches to selectively target pathogenic JAK2 signaling.
PubMed: 38457493
DOI: 10.1126/sciadv.adl2097
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.7 Å)
構造検証レポート
Validation report summary of 8c0a
検証レポート(詳細版)ダウンロードをダウンロード

237423

件を2025-06-11に公開中

PDB statisticsPDBj update infoContact PDBjnumon